This study will evaluate the safety, tolerability, and systemic exposure of an experimental
influenza (flu) treatment medication called DAS181. DAS181 is a dry powder that is
administered via oral inhalation using a special device. Study participants will include up
to 60 healthy, non-smoking males and females, ages 18-65. They will be given either DAS181 or
placebo. Participants will remain in the clinic overnight to be watched for health changes
for 24 hours after receiving the medication. Study procedures include: physical exams, chest
x-rays, ECGs, lung function tests, collection of blood and urine samples, and throat swabs.
Follow-up visits will occur on study days 2, 7, 14 +/- 1 day, and 30 +/- 2 days. Participants
will be involved in the study for up to 61 days, which includes the screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Ansun Biopharma, Inc.
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)